文献速递神经儿科影像MR

儿童低级别胶质瘤中的T2-FLAIR错配征

T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
PubMed 文献 · AJNR Am J Neuroradiol · 2023-06-22

本研究回顾性纳入2001年1月至2018年8月349例儿童低级别胶质瘤患者,评估T2-FLAIR错配征的意义。错配征见于25例(7.2%),均无BRAF p.V600E突变,其中14例携带罕见分子变异,11例分子亚型未知。错配征未见于常见的BRAF p.V600E突变和KIAA1549-BRAF融合型肿瘤。

要点

  • 儿童低级别胶质瘤中T2-FLAIR错配征出现率低(7.2%),阅片时不应作为常见征象期待。
  • 错配征阳性肿瘤均无BRAF p.V600E突变,且多携带罕见分子变异。
  • 错配征在儿童低级别胶质瘤中的分子意义与成人IDH突变型胶质瘤不同。

核心结论

  • T2-FLAIR错配征未见于常见的BRAF p.V600E突变和KIAA1549-BRAF融合型儿童低级别胶质瘤,而见于携带罕见儿童分子变异的肿瘤。

研究设计与样本

  • 回顾性研究,纳入2001年1月至2018年8月儿童低级别胶质瘤患者349例(187例男孩;平均年龄8.7岁,标准差4.8;范围0.5-17.7岁),纳入标准为年龄0-18岁、组织病理学确诊且有分子信息、术前脑MR成像含非运动伪影T2加权和FLAIR序列,排除脊髓肿瘤。

关键影像表现/征象

  • T2-FLAIR错配征见于25例(7.2%),包括9例胚胎发育不良性神经上皮肿瘤、8例低级别星形细胞瘤、5例弥漫性星形细胞瘤、1例毛细胞型星形细胞瘤、1例胶质神经元肿瘤和1例血管中心性胶质瘤。

诊断标准与关键数值

  • T2-FLAIR错配征在349例儿童低级别胶质瘤中阳性25例(7.2%)。
  • 25例错配征阳性肿瘤中,0例为BRAF p.V600E突变。
  • 25例错配征阳性肿瘤中,14例携带罕见分子变异,11例分子亚型未知。

临床应用与阅片要点

  • 阅片时若见T2-FLAIR错配征,提示肿瘤可能不携带BRAF p.V600E突变或KIAA1549-BRAF融合,而可能属于携带罕见分子变异的儿童低级别胶质瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: No qualitative imaging feature currently predicts molecular alterations of pediatric low-grade gliomas with high sensitivity or specificity. The T2-FLAIR mismatch sign predicts IDH-mutated 1p19q noncodeleted adult gliomas with high specificity. We aimed to assess the significance of the T2-FLAIR mismatch sign in pediatric low-grade gliomas.

MATERIALS AND METHODS: Pretreatment MR images acquired between January 2001 and August 2018 in pediatric patients with pediatric low-grade gliomas were retrospectively identified. Inclusion criteria were the following: 1) 0-18 years of age, 2) availability of molecular information in histopathologically confirmed cases, and 3) availability of preoperative brain MR imaging with non-motion-degraded T2-weighted and FLAIR sequences. Spinal cord tumors were excluded.

RESULTS: Three hundred forty-nine patients were included (187 boys; mean age, 8.7 [SD, 4.8] years; range, 0.5-17.7 years). KIAA1549-B-Raf proto-oncogene (BRAF) fusion and BRAF p.V600E mutation were the most common molecular markers (n = 148, 42%, and n = 73, 20.7%, respectively). The T2-FLAIR mismatch sign was present in 25 patients (7.2%). Of these, 9 were dysembryoplastic neuroepithelial tumors; 8, low-grade astrocytomas; 5, diffuse astrocytomas; 1, a pilocytic astrocytoma; 1, a glioneuronal tumor; and 1, an angiocentric glioma. None of the 25 T2-FLAIR mismatch pediatric low-grade gliomas were BRAF p.V600E-mutated. Fourteen of 25 pediatric low-grade gliomas with the T2-FLAIR mismatch sign had rare molecular alterations, while the molecular subtype was unknown for 11 tumors.

CONCLUSIONS: The T2-FLAIR mismatch sign was not observed in the common molecular alterations, BRAF p.V600E-mutated and KIAA1549-BRAF fused pediatric low-grade gliomas, while it was encountered in pediatric low-grade gliomas with rare pediatric molecular alterations.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Wagner, Nobre, Namdar, et al. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma. AJNR Am J Neuroradiol. 2023. PMID: 37348970. doi:10.3174/ajnr.A7916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。